Trial Outcomes & Findings for Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection (NCT NCT00304356)

Results Overview

stopping of diarrhea

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

22 participants

Primary outcome timeframe

30 days

Results posted on

2017-12-15

Chart review at the Houston VA for patients treated with Nitazoxanide who have failed previous therapy.

This is a retrospective chart review.

Reasons for withdrawal
Measure	Nitazoxanide
Nitazoxanide Physician Decision	1
Nitazoxanide number is 0	1

Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection

Baseline characteristics by cohort
Measure	Nitazoxanide n=27 Participants Patients with C. difficle who exhibit diarrhea and received nitazoxanide.
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	27 Participants n=5 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants
Age, Continuous	27 years STANDARD_DEVIATION 27 • n=5 Participants
Sex: Female, Male Female	0 Participants n=5 Participants
Sex: Female, Male Male	27 Participants n=5 Participants
Region of Enrollment United States	27 participants n=5 Participants

Timeframe: 30 days

stopping of diarrhea

Outcome measures
Measure	Nitazoxanide n=27 Participants time diarrhea from C. difficile stopped.
Nitazoxanide	27 participants

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

VA Houston

Phone: 713-794-7386